Redemplo (plozasiran) cleared for familial chylomicronemia syndrome at $60,000 annual price—ten times lower than competitor
Arrowhead Pharmaceuticals achieved a transformational milestone on November 18, 2025, with FDA approval of Redemplo (plozasiran), marking the company’s first regulatory clearance after more than two decades of RNA interference research and development. The approval positions Arrowhead as a commercial-stage biotechnology company but also sets up an immediate marketplace battle with rival Ionis Pharmaceuticals, whose competing therapy Tryngolza was approved for the same rare metabolic disease just one year earlier.
Landmark Approval Addresses Critical Unmet Need
Redemplo received approval as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a severe rare disease affecting an estimated 6,500 people in the United States. FCS stems from impaired function of an enzyme important to triglyceride metabolism, leading to blood triglyceride levels that can reach 10 to 100 times higher than normal range.
The disease causes debilitating symptoms including fatigue, severe brain fog, and recurrent abdominal pain. Most seriously, about 93% of acute pancreatitis episodes—the life-threatening complication of FCS—result in inpatient hospitalization averaging 10 days and costing approximately $60,000 per episode.
“The FDA approval of REDEMPLO is a transformational milestone for Arrowhead,” said CEO Christopher Anzalone, Ph.D. “This is a proud moment for all those involved in the discovery and development process and represents new hope for the estimated 6,500 people in the U.S. living with genetic or clinical FCS”.
Mechanism of Action: Silencing ApoC-III Production
Redemplo is a small interfering RNA (siRNA) therapy that utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM) platform to suppress production of apolipoprotein C-III (apoC-III), a liver protein that raises triglyceride levels by slowing the breakdown and clearance of these fats.
The self-administered subcutaneous injection requires dosing only once every three months, offering a significant convenience advantage over daily or monthly regimens. This quarterly dosing schedule reflects the durable knockdown of apoC-III production achieved through the RNAi mechanism.
Phase 3 PALISADE Data Demonstrate Deep, Durable Efficacy
FDA approval was supported by results from the Phase 3 PALISADE study, which met its primary endpoint and all multiplicity-controlled key secondary endpoints. In the randomized, double-blind, placebo-controlled trial, the 25 mg dose of Redemplo achieved deep and durable reductions in triglycerides, with a median change from baseline of -80% compared to -17% in the pooled placebo group at the primary timepoint.
The study also demonstrated significant reductions in apoC-III levels and a numerically lower incidence of acute pancreatitis compared with placebo. Detailed results were published in the New England Journal of Medicine and Circulation, providing peer-reviewed validation of the clinical benefit.
The drug’s prescribing information notably contains no boxed warnings or contraindications, suggesting a favorable regulatory assessment of the benefit-risk profile. The most common adverse reactions in clinical trials included hyperglycemia, headache, nausea, and injection site reactions.
Aggressive Pricing Strategy Takes Aim at Ionis Market Position
Arrowhead announced Redemplo will launch with an annual wholesale acquisition cost of $60,000—a price point that sent shockwaves through the rare disease sector. This represents approximately one-tenth the $595,000 annual list price that Ionis set for Tryngolza when it became the first FDA-approved FCS therapy in December 2024.
CEO Anzalone explained the strategic rationale during a conference call: “Ultimately, the large economic opportunity here is in the SHTG population, and so it’s critical that we get the right price for that, and if that means that we give up some short-term revenue in FCS, we view that as an investment in the future”.
Arrowhead committed to maintaining this $60,000 price across all current and future indications for Redemplo, including the larger severe hypertriglyceridemia (SHTG) market where an estimated 1 million patients with high-risk disease face elevated acute pancreatitis risk. By contrast, Ionis has indicated Tryngolza could be priced around $20,000 for SHTG.
Head-to-Head Comparison Favors Arrowhead on Multiple Dimensions
Beyond pricing, Arrowhead positions Redemplo as superior to Tryngolza across several key parameters. The quarterly injection schedule contrasts favorably with Tryngolza’s monthly injections, reducing treatment burden for patients.
Cross-trial comparisons, while requiring caution, suggest Redemplo may offer greater efficacy. In Phase 3 testing, Redemplo demonstrated about a 70% reduction in triglycerides compared to placebo after one year, versus 59% for Tryngolza. The difference in median percent change from baseline was also striking: -80% for Redemplo versus approximately -59% for Tryngolza at the primary analysis timepoint.
Safety profiles also differentiate the two therapies. Tryngolza’s label carries a warning for hypersensitivity reactions, which were the most common reason for treatment discontinuation in clinical trials. Redemplo’s prescribing information includes no such warning, potentially offering physicians and patients greater confidence in tolerability.
Leerink Partners analyst Mani Foroohar noted in an investor note that Redemplo’s price “was a surprise,” adding that “the labels for the two FCS drugs are largely similar, with the main difference being the dosing frequency”.
Broader Pipeline Opportunity in Severe Hypertriglyceridemia
While FCS represents the initial approval, both Arrowhead and Ionis are pursuing the substantially larger SHTG indication. Unlike FCS, which has a genetic cause, SHTG results from a combination of genetic, medical, and lifestyle factors and affects an estimated 3 million people, with about 1 million having high-risk SHTG.
Ionis has already succeeded in a late-stage trial for SHTG, while Arrowhead could release study results next year according to ClinicalTrials.gov. Arrowhead frames Redemplo as treating pancreatitis regardless of its cause, positioning the drug broadly across the triglyceride disorder spectrum rather than as narrowly indicated for genetic FCS alone.
“The real economic opportunity here, and our focus, at least in terms of economics, is making sure that [SHTG] is properly priced, and the way we look at it, the initial population here is the high-risk SHTG patients,” Anzalone explained.
Arrowhead executives indicated the company projects multi-billion-dollar revenue potential across multiple indications for Redemplo. The therapy is also being investigated in the MUIR Phase 3 study in patients with mixed hyperlipidemia, further expanding the addressable market.
Patent Litigation Shadow Looms Over Commercial Launch
The commercial competition between Arrowhead and Ionis extends beyond clinical and pricing dimensions into intellectual property territory. In September 2025, the companies filed dueling lawsuits, with Ionis accusing Arrowhead of infringing on patents and Arrowhead asking a court to declare that the patent is either invalid or not infringed upon.
This patent dispute could cast uncertainty over Redemplo’s commercial trajectory, potentially affecting payer coverage decisions and physician prescribing patterns until resolved. The pharmaceutical industry has witnessed numerous examples where IP litigation has complicated rare disease product launches and market dynamics.
Arrowhead’s Broader RNA Interference Platform Gains Validation
The Redemplo approval validates Arrowhead’s TRiM platform technology and broader RNAi capabilities after years of research investment. Unlike its larger counterpart Alnylam Pharmaceuticals, which has several approved products and a market value around $60 billion, Arrowhead had remained pre-commercial with a much smaller market capitalization—though its worth has more than doubled in 2025.
The company has amassed a pipeline of more than a dozen RNAi medicines and formed multiple partnership deals, including an $825 million upfront deal with Sarepta Therapeutics in November 2024 that could reach $10 billion with milestones. Arrowhead has demonstrated the capability to deliver RNAi medicines to multiple different cell types, supporting a broad platform approach.
“This approval, and subsequent launch, marks the beginning of a new chapter in our journey—one rooted in our unwavering commitment to delivering life-changing therapies to patients with serious diseases,” Anzalone stated.
Market Access and Physician Adoption Will Determine Winner
Near-term uptake of both Redemplo and Tryngolza will be driven by commercial execution, pricing and access dynamics, and physician preferences based on perceived efficacy and safety profiles. Leerink analyst Mani Foroohar noted that based on discussions with clinicians, “excitement is high for both drugs. Physicians see the safety profiles as manageable, and the firm views the triglyceride-lowering opportunity split between the two drugs”.
For the first nine months of 2025, Ionis reported $57.3 million in Tryngolza revenue, representing the first product Ionis has commercialized without a partner. This established market presence gives Ionis a head start in patient identification, physician education, and payer contracting.
However, Arrowhead’s aggressive pricing strategy and clinical profile advantages could enable rapid market penetration. The company expects Redemplo to become available to FCS patients by the end of 2025. As for global commercialization, Anzalone indicated Arrowhead is open to finding a partner but is not dependent on one.
The FCS and SHTG markets represent a test case for how innovation-focused biotechnology companies can compete with established players through differentiated clinical profiles and value-based pricing strategies. The outcome will be closely watched by pharmaceutical executives, investors, and health policy stakeholders as models for rare disease commercialization evolve.
